Business case
Our client, a global leader in pharmaceutical wholesale, sought to refine its long-term strategy in France. The pharmaceutical value chain was experiencing significant market developments including substitution from generics, growth of para-pharmaceutical products, deregulation of retail constraints and market concentration, development of e-commerce, greater prioritisation of prevention services, and innovation in logistics solutions.
We issued clear recommendations on how to turn the business model towards the most attractive segments. We also delivered fact-based guidance on necessary investments, as well as possible divestments from non-core activities. We supported the executive committee with the necessary management presentation to the board.
We were engaged to work on our client’s long-term strategy in the country. In particular, we launched a full portfolio review of our client’s activities (eight business units). For each BU, we were able to draw a clear view on its segmented profitability, market dynamics and competitive position. We also strengthened our quantitative analyses, thanks to high-level external interviews throughout the value chain, as well as through open business interviews with all the directors of the group.